475 related articles for article (PubMed ID: 26587974)
1. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
3. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
Lu L; Luo F; Liu Y; Liu X; Shi L; Lu X; Liu Q
Toxicol Appl Pharmacol; 2015 Dec; 289(2):276-85. PubMed ID: 26415832
[TBL] [Abstract][Full Text] [Related]
4. Snail and Slug collaborate on EMT and tumor metastasis through miR-101-mediated EZH2 axis in oral tongue squamous cell carcinoma.
Zheng M; Jiang YP; Chen W; Li KD; Liu X; Gao SY; Feng H; Wang SS; Jiang J; Ma XR; Cen X; Tang YJ; Chen Y; Lin YF; Tang YL; Liang XH
Oncotarget; 2015 Mar; 6(9):6797-810. PubMed ID: 25762643
[TBL] [Abstract][Full Text] [Related]
5. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.
Dong P; Karaayvaz M; Jia N; Kaneuchi M; Hamada J; Watari H; Sudo S; Ju J; Sakuragi N
Oncogene; 2013 Jul; 32(27):3286-95. PubMed ID: 22847613
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
Song QC; Shi ZB; Zhang YT; Ji L; Wang KZ; Duan DP; Dang XQ
Oncol Rep; 2014 Mar; 31(3):1263-70. PubMed ID: 24452597
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
9. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
[TBL] [Abstract][Full Text] [Related]
11. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
[TBL] [Abstract][Full Text] [Related]
13. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.
Sharma H; Estep M; Birerdinc A; Afendy A; Moazzez A; Elariny H; Goodman Z; Chandhoke V; Baranova A; Younossi ZM
J Gastroenterol Hepatol; 2013 Aug; 28(8):1410-5. PubMed ID: 23663110
[TBL] [Abstract][Full Text] [Related]
14. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
15. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2.
Zhang Y; Lin C; Liao G; Liu S; Ding J; Tang F; Wang Z; Liang X; Li B; Wei Y; Huang Q; Li X; Tang B
Oncotarget; 2015 Oct; 6(32):32586-601. PubMed ID: 26452129
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma.
Huang SD; Yuan Y; Zhuang CW; Li BL; Gong DJ; Wang SG; Zeng ZY; Cheng HZ
Mol Cancer; 2012 Aug; 11():51. PubMed ID: 22867052
[TBL] [Abstract][Full Text] [Related]
20. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.
Seward S; Semaan A; Qazi AM; Gruzdyn OV; Chamala S; Bryant CC; Kumar S; Cameron D; Sethi S; Ali-Fehmi R; Morris R; Bouwman DL; Munkarah AR; Weaver DW; Gruber SA; Batchu RB
Cancer Lett; 2013 Aug; 336(1):53-60. PubMed ID: 23603558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]